What is the primary product offering of Sharps Technology?

Sharps Technology focuses on 'Smart Safety Syringes' and Prefillable Syringe (PFS) systems. According to Slide 7, these are engineered for efficient drug containment using advanced polymer materials that offer glass-like transparency, high break resistance, and improved drug stability. The products are designed to be ultra-low waste and include automatic safety shields to prevent needle-stick injuries.

How does the company plan to generate revenue?

The company is transitioning to commercialization through a major partnership. Slide 4 and Slide 22 highlight a 10-year, $400 million purchase agreement with Nephron Pharmaceuticals. Revenue is expected to commence in Q1 2024. They are targeting large pharmaceutical players like Pfizer, Moderna, and AbbVie, as indicated by the 'Target Audience' map on Slide 10.

What is the current financial standing of the company?

As of the October 2023 deck, Sharps Technology is a micro-cap public company listed on Nasdaq (STSS). Slide 22 lists a market cap of ~$9.5 million and 18.7 million common shares outstanding. They reported $0 debt and recently raised $5.6 million in September 2023 to support their manufacturing and commercialization efforts.

What manufacturing assets does Sharps Technology own?

The company has two primary manufacturing pillars. Slide 4 notes the July 2022 acquisition of the Safegard Medical facility in Hungary, which is FDA-cleared and ISO-certified. Additionally, Slide 4 and 22 mention the September 2023 agreement to acquire the InjectEZ facility in South Carolina as part of the Nephron Pharmaceuticals partnership.

Who is leading the company through this commercial transition?

The leadership team, detailed on Slide 19, features significant industry veterans. CEO Robert Hayes has 25 years of experience, including roles at Gerresheimer and Baxter. Chairman Soren Bo Christiansen, MD, is a former Merck President, and CMO Steven Hertz, MD, provides clinical oversight. This high-level expertise is intended to provide credibility for their $400M contract execution.

Sharps Technology, Inc. Pitch Deck (2023) Breakdown

See all 23 slides of the Sharps Technology, Inc. pitch deck, with a slide-by-slide teardown of what the deck does well and where it falls short.

Sharps Technology, Inc. (Nasdaq: STSS) is a medical device company specializing in smart safety and prefillable syringe systems. As of October 2023, the company is in a critical transition phase, moving from a pre-revenue R&D entity to a commercial manufacturer. The deck centers on a transformative 10-year, $400 million purchase agreement with Nephron Pharmaceuticals and the acquisition of the InjectEZ manufacturing facility. Despite a modest market cap of ~$9.5M and being pre-revenue, the company leverages a robust IP portfolio of 25+ patents and a leadership team with deep industry experien…

Key takeaways

The company completed its IPO in April 2022, raising $16 million (Slide 4).
A transformative 10-year purchase agreement for over $400 million was signed with Nephron Pharmaceuticals in September 2023 (Slide 4).
The company is currently pre-revenue, with first sales projected for Q1 2024 (Slide 22).
Manufacturing capabilities are split between an ISO-certified facility in Hungary and a partnership in South Carolina (Slide 22).
The IP portfolio includes multiple active and pending patents for ultra-low-waste and safety-shielded syringe systems across the US, EU, Japan, and Australia (Slide 16).
As of late 2023, the company had a market cap of approximately $9.5 million with a share price of $0.84 (Slide 22).
The leadership team includes a Chairman who was a former Merck President with P&L responsibility for $10 billion (Slide 19).
The company reported a cash balance of ~$4.1 million as of 12/31/22 and a recent raise of $5.6 million in September 2023 (Slide 22).

Executive Summary and Introduction

Slide 1: Title Slide

The cover slide introduces Sharps Technology, Inc. (Nasdaq: STSS) with the tagline: "Collaboration. Innovation. Novel Technology. Making the World a Healthier Place." The visual features a 3D render of a syringe tray and individual syringes, emphasizing the physical product nature of the business. The slide is dated October 2023, positioning it shortly after a significant capital raise and contract signing.

Slide 4: Significant Developments

This slide serves as a historical timeline and traction summary. Key milestones include the company's founding in 2017 and the development of a product line that is FDA, WHO, and CE Mark approved. Crucially, it mentions that products are cleared for use by Pfizer and Moderna. The slide highlights the April 2022 IPO which raised $16M and the July 2022 acquisition of a manufacturing facility in Hungary at a "significant discount." The most vital piece of information is the September 2023 asset purchase agreement for the InjectEZ facility and a 10-year, $400 million purchase agreement from Nephron Pharmaceuticals. This slide establishes the company's shift from a development-stage entity to a commercial-scale manufacturer.

Product and Technology Deep Dive

Slide 7: Prefillable Syringes (PFS)

Slide 7 focuses on the technical specifications of the Prefillable Syringe systems. It outlines a "Proven Process" involving precision molds, advanced polymer materials, and ISO clean room assembly. The "Delivery Systems" section lists benefits such as glass-like transparency, high break resistance, and moisture barriers for drug stability. The slide explicitly states that PFS is a "strong preference in the medical industry over vial draw disposable syringes," positioning the company within a high-demand market segment. The visual includes a high-resolution render of a syringe with a safety closure.

Slide 10: Target Audience

This slide uses a global map to visualize the company's market opportunity and existing supplier ecosystem. It identifies "North American Suppliers" (BD), "Japanese Suppliers" (Taisei Kako, Terumo), and "European Suppliers" (Schott, Gerresheimer, Stevanato Group). More importantly, it maps out potential and current pharmaceutical partners, including Pfizer (Cold Chain Vaccines), Amgen (Multiple Biologics), AbbVie (BOTOX), and Nephron (Multiple 503B). This slide communicates the scale of the pharmaceutical companies Sharps intends to serve, suggesting a large Total Addressable Market (TAM).

Slide 13: Sharps Disposable Syringes Product Line

This is a transition slide featuring an architectural render of a manufacturing facility. The text emphasizes "Smart Safety Syringes designed for minimal waste and eco friendly initiatives." This aligns the company with ESG (Environmental, Social, and Governance) trends in healthcare, specifically addressing the waste generated by billions of disposable syringes annually.

Intellectual Property and Governance

Slide 16: Existing Patents

Slide 16 provides a comprehensive table of the company's intellectual property. It lists 25 patent entries across various jurisdictions including the United States, Australia, Canada, Europe, and Japan. The patents cover "Needle and syringe system with automatic safety shield," "Pre-filled safety needle," and "Ultra-low-waste disposable syringe." The status column shows a mix of "Active" and "Pending" applications. This slide is critical for a medical technology company, as it demonstrates the defensibility of their technology and the global scope of their IP protection.

Slide 19: Leadership Team

The leadership slide features four key executives. Robert Hayes (CEO) is credited with 25 years of healthcare experience at firms like Gerresheimer and Baxter. Soren Bo Christiansen, MD (Chairman) is highlighted as a former Merck President with $10B P&L responsibility. Andrew Crescenzo, CPA (CFO) and Steven Hertz, MD (CMO) round out the team with backgrounds in biotech finance and vascular surgery, respectively. The presence of a former Merck President on the board is a significant credibility marker for a micro-cap company.

Financials and Market Position

Slide 22: Key Statistics

The final slide in the provided set offers a snapshot of the company's public market data and financial health as of late 2023. Key figures include:

Market Cap: ~$9.5M · Share Price: $0.84 · Fully Diluted Shares: 41.5M · Insider Ownership: 16% · Revenue: Pre-revenue, with sales expected Q1 2024 · Cash: ~$4.1M (as of 12/31/22) plus a $5.6M raise on 9/29/23 · Debt: 0 · Employees: ~60

This slide is transparent about the company's pre-revenue status but points to the imminent Q1 2024 sales launch as the primary catalyst for investors.

What Sharps Technology Does Well

The deck excels at establishing credibility through association . By listing Pfizer, Moderna, and Merck (via their Chairman) and highlighting a $400 million contract with Nephron, the company mitigates the perceived risk of its small market cap. The inclusion of a detailed patent list (Slide 16) provides the technical due diligence necessary for medical device investors. Furthermore, the clear distinction between their two manufacturing hubs (Hungary and South Carolina) shows a concrete path to fulfilling the large Nephron contract.

What is Missing from the Deck

While the deck is strong on IP and partnerships, it lacks detailed unit economics . There is no mention of the manufacturing cost per unit versus the expected sale price, which is vital for understanding the path to profitability once revenue starts. Additionally, while the "Target Audience" slide (Slide 10) lists many big names, it does not clearly distinguish between "active customers," "signed pilots," and "prospective leads," other than the specific Nephron deal. Finally, there is no competitor comparison matrix ; while they list other suppliers like BD and Schott, they do not explicitly state how their "Smart Safety" technology outperforms these incumbents on cost or safety metrics.

Founder's Takeaway: What to Copy

Founders of pre-revenue hardware or med-tech companies should emulate the milestone-heavy traction slide (Slide 4). Instead of just listing goals, Sharps lists specific regulatory approvals (FDA, WHO, CE) and specific dollar amounts for acquisitions and raises. The Key Statistics slide (Slide 22) is also a model of transparency for public or late-stage private companies, providing a one-stop shop for valuation, share count, and cash position. Lastly, the IP table (Slide 16) is a professional way to present a complex patent portfolio, showing not just that they have patents, but where they are filed and their current status, which builds significant trust during the due diligence process.

Frequently asked questions

What is the primary product offering of Sharps Technology?: Sharps Technology focuses on 'Smart Safety Syringes' and Prefillable Syringe (PFS) systems. According to Slide 7, these are engineered for efficient drug containment using advanced polymer materials that offer glass-like transparency, high break resistance, and improved drug stability. The products are designed to be ultra-low waste and include automatic safety shields to prevent needle-stick injuries.
How does the company plan to generate revenue?: The company is transitioning to commercialization through a major partnership. Slide 4 and Slide 22 highlight a 10-year, $400 million purchase agreement with Nephron Pharmaceuticals. Revenue is expected to commence in Q1 2024. They are targeting large pharmaceutical players like Pfizer, Moderna, and AbbVie, as indicated by the 'Target Audience' map on Slide 10.
What is the current financial standing of the company?: As of the October 2023 deck, Sharps Technology is a micro-cap public company listed on Nasdaq (STSS). Slide 22 lists a market cap of ~$9.5 million and 18.7 million common shares outstanding. They reported $0 debt and recently raised $5.6 million in September 2023 to support their manufacturing and commercialization efforts.
What manufacturing assets does Sharps Technology own?: The company has two primary manufacturing pillars. Slide 4 notes the July 2022 acquisition of the Safegard Medical facility in Hungary, which is FDA-cleared and ISO-certified. Additionally, Slide 4 and 22 mention the September 2023 agreement to acquire the InjectEZ facility in South Carolina as part of the Nephron Pharmaceuticals partnership.
Who is leading the company through this commercial transition?: The leadership team, detailed on Slide 19, features significant industry veterans. CEO Robert Hayes has 25 years of experience, including roles at Gerresheimer and Baxter. Chairman Soren Bo Christiansen, MD, is a former Merck President, and CMO Steven Hertz, MD, provides clinical oversight. This high-level expertise is intended to provide credibility for their $400M contract execution.

Cover slide of the Sharps Technology, Inc. pitch deck — Public (Nasdaq: STSS) 2023 — Sharps Technology, Inc. pitch deck, slide 1 (2023)

Sharps Technology, Inc. pitch deck: the facts

Company: Sharps Technology, Inc.
Year: 2023
Stage: Public (Nasdaq: STSS)
Slides: 23
Sector: Medical Device / Healthcare
Deck type: Investor Presentation
Outcome: Active / Post-Raise ($5.6M in Sept 2023)
Headquarters: Melville, NY

Sharps Technology, Inc. pitch deck PDF

The full Sharps Technology, Inc. deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Sharps Technology, Inc. pitch deck was used for

This deck is an **October 2023 investor presentation** for Sharps Technology, Inc. (Nasdaq: STSS), a publicly listed micro‑cap medical device company focused on safety and prefillable syringes. The presentation centers on Sharps’ transition from primarily R&D to commercial scale by acquiring Nephron Pharmaceuticals’ InjectEZ specialty copolymer prefillable syringe manufacturing facility and securing a **10‑year purchase agreement for over $400 million** of syringes from Nephron. The deck positions this deal as the company’s entry into large‑scale copolymer prefillable syringe production with revenue expected to commence following the facility acquisition and start‑up of operations.

Business model: Sharps Technology, Inc. is a medical device company focused on **safety syringes and prefillable drug delivery systems**, including next‑generation copolymer prefillable syringes, targeting healthcare providers and pharmaceutical/biotech manufacturers.

Year: 2023

Round: Public company transaction (asset purchase and associated long‑term purchase agreement) disclosed via SEC filings and press releases in 2023.

Industry: Medical devices / drug delivery systems, including safety syringes and prefillable syringe technology.

Use of funds as presented: Sharps disclosed that proceeds from the planned debt financing (up to $75 million) would be used primarily to fund the approximately $50 million acquisition of the InjectEZ specialty copolymer syringe manufacturing facility and to support expansion of its prefillable syringe manufacturing operations.

What happened after the Sharps Technology, Inc. deck

As of the October 2023 investor deck and related filings, Sharps Technology had signed an Asset Purchase Agreement to acquire Nephron’s InjectEZ specialty copolymer syringe manufacturing facility for approximately $50 million and a ten‑year purchase agreement under which Nephron committed to purchase a minimum of at least $400 million of prefilled copolymer syringes, supported by a term sheet for

On September 19, 2023, Sharps Technology entered into a ten‑year purchase agreement with Nephron under which Nephron agr
On September 22, 2023, Sharps executed an Asset Purchase Agreement to acquire Nephron’s InjectEZ specialty syringe manuf
Sharps announced that it had signed a term sheet providing for up to $75 million in debt financing intended to fund the
Company and third‑party descriptions of the October 2023 investor presentation indicate that Sharps planned to bring the

What the Sharps Technology, Inc. deck got right

Anchored by a large, long‑term customer contract. The deck centers on a **10‑year purchase agreement** with Nephron Pharmaceuticals under which Nephron agreed to purchase a minimum aggregate of at least **$400 million** of copolymer prefilled syringes, providing a large, contracted demand base that underpins the growth narrative.
Clear strategic linkage between facility acquisition and revenue. Sharps pairs the Nephron supply agreement with the planned **$50 million acquisition of the InjectEZ specialty copolymer syringe facility**, clearly linking contracted demand to control over a dedicated manufacturing asset.
Exclusive supplier positioning with a marquee customer. The deck highlights that Sharps will become Nephron’s **exclusive pre‑filled copolymer syringe manufacturer**, positioning the company as a key partner rather than a commodity supplier and supporting a differentiated role in the prefillable syringe ecosystem.
Geographically diversified manufacturing footprint. Company communications around the deck emphasize that Sharps will have manufacturing operations in both **Europe and the United States**, which can reassure investors about supply resilience and the ability to serve global pharmaceutical clients.
Coherent evolution from safety syringes to prefillable systems. The presentation builds on Sharps’ existing safety syringe and drug delivery technology platform, showing continuity between its prior R&D focus and the new prefillable syringe opportunity rather than portraying the InjectEZ acquisition as a complete strategic pivot.
Strong alignment between deck messaging and filed disclosures. Key claims in the deck—such as the size and terms of the Nephron agreement and InjectEZ acquisition—are supported by contemporaneous SEC filings and official press releases, enhancing credibility for public‑market investors reviewing the presentation.

What could have been stronger

Sparse disclosure of key commercial risks around the Nephron contract. The deck heavily emphasizes the 10‑year, $400+ million Nephron purchase agreement but does not (in the publicly viewable materials) clearly disclose conditions precedent, termination clauses, or volume flexibility that could materially affect how much revenue is ultimately realized from the contract.
Limited visibility into leverage and post‑deal capital structure. Public filings and press releases describe a **$50 million** acquisition price for the InjectEZ facility and a term sheet for up to **$75 million** of debt financing, but the deck materials available do not provide a transparent, detailed pro forma capital structure, leverage metrics, or interest burden, making it difficult for investors to assess financial risk.
Light disclosure on historical operating performance relative to future scale. The deck’s narrative focuses on future revenue from the InjectEZ acquisition and Nephron contract; based on accompanying materials, Sharps was still a small‑cap company with modest current revenues, and the deck provides limited quantified historical performance to validate execution capability at the scale implied by a $400M contract.
Insufficient competitive context in publicly visible materials. Although Sharps positions itself as entering a large prefillable syringe market, the publicly accessible deck description does not set out a detailed competitive landscape or comparative advantages against major incumbents in prefilled syringes, which would help investors benchmark the opportunity.

How an investor would read this deck

What draws attention

The deck’s central focus is the **asset purchase of Nephron’s InjectEZ copolymer prefillable syringe manufacturing facility** for approximately **$50 million**.
The associated **10‑year purchase agreement with Nephron for over $400 million** of minimum syringe purchases, making Nephron a key long‑term customer and anchor revenue source.
The strategic shift from a primarily R&D‑oriented safety syringe company to a vertically integrated manufacturer with facilities in both **Europe and the United States**, as mentioned by company communications.
Expected revenue ramp from the Nephron contract and InjectEZ facility, including early‑year and steady‑state revenue expectations referenced in summaries of the October 2023 investor materials.
The announced term sheet for up to **$75 million in debt financing** to fund the InjectEZ acquisition and its implications for Sharps’ balance sheet and cost of capital.

Risks that stand out

Execution risk in completing the **InjectEZ** acquisition, integrating the facility, and scaling manufacturing to meet Nephron’s volume commitments, including potential delays, cost overruns, or regulatory hurdles.
Customer concentration risk, as the **Nephron purchase agreement** appears to represent a large share of projected future revenues, exposing Sharps to material impact from any changes in Nephron’s demand or contractual relationship.
Financial risk stemming from the **$50 million acquisition price** and the planned **up to $75 million debt financing**, which could significantly increase leverage and fixed obligations for a micro‑cap company.
Market and competitive risk in the prefillable syringe sector, where established global players may respond aggressively, potentially pressuring pricing, contract terms, or customer acquisition.
Regulatory and quality risks inherent in manufacturing prefillable syringe systems for pharmaceutical customers, where compliance failures could delay revenue, trigger remediation costs, or jeopardize key contracts.

Questions this deck invites

What specific conditions precedent, performance milestones, pricing mechanisms, and termination clauses are included in the 10‑year, $400M+ Nephron purchase agreement, and under what circumstances could volumes or commitments be reduced or
What is the detailed pro forma capital structure (including terms of the up to $75M debt financing) after the InjectEZ acquisition, and how do projected interest and principal payments compare to expected cash flows from the Nephron contrac
What capital expenditures, validation activities, and regulatory approvals are required to bring the InjectEZ facility to full commercial operation, and what timeline, budget, and contingency plans has Sharps established for this ramp‑up?
How does Sharps’ copolymer prefillable syringe technology compare technically and economically with competing glass and plastic prefillable syringe systems, and what barriers to entry or IP protections support durable margins?
What diversification strategy does Sharps have beyond the Nephron contract to avoid over‑reliance on a single customer, and what is the current pipeline of other pharmaceutical or healthcare customers for its prefillable syringes and safety

What founders can take from the Sharps Technology, Inc. deck

Anchoring a micro‑cap medical device growth story around a **large, multi‑year purchase agreement** with a credible customer (Nephron Pharmaceuticals) can provide a compelling revenue narrative if it is clearly documented and supported by filed agreements.
Pairing a **facility acquisition** (InjectEZ) with a long‑term supply contract illustrates how control over specialized manufacturing assets can be directly linked to contracted demand, strengthening the strategic logic for investors.
Explicitly disclosing transaction terms such as the **$50 million acquisition price** and the associated **debt financing term sheet** gives investors concrete numbers around which to evaluate risk/return, even if it also highlights leverage concerns.
Highlighting a transition from **R&D‑focused safety syringes to commercial‑scale prefillable syringe manufacturing** can reposition a small medical device company as a platform‑scale player, but it requires consistent messaging about operational readiness and customer commitments.
Securing geographical diversification of manufacturing (e.g., operations in Europe and the United States) can be used in a deck to signal resilience and the ability to serve global pharmaceutical customers, particularly when tied to a flagship contract.
Using an **investor presentation** closely aligned with contemporaneous SEC filings and press releases reinforces credibility, as investors can cross‑check deck claims (such as the $400M Nephron agreement) against legally binding disclosures.

Sharps Technology, Inc. pitch deck: common questions

What does Sharps Technology, Inc. do?

Sharps Technology is a medical device company listed on Nasdaq under the ticker **STSS**, focused on advanced safety syringes and next‑generation copolymer prefillable syringe systems for the healthcare and pharmaceutical markets.

What is the main focus of Sharps Technology’s October 2023 investor deck?

The October 2023 investor deck highlights an **asset purchase agreement** to acquire Nephron Pharmaceuticals’ InjectEZ specialty copolymer syringe manufacturing facility and a **10‑year purchase agreement for over $400 million** of prefillable syringes to be supplied to Nephron.

What is the $400 million purchase agreement mentioned in the deck?

According to the company’s September 2023 disclosures, Sharps agreed to acquire the InjectEZ facility for **$50 million** and signed a **10‑year purchase agreement** with Nephron under which Nephron committed to purchase a minimum aggregate of at least **$400 million** of copolymer prefilled syringes over the term of the agreement.

How firm is the Nephron purchase commitment and how is it presented in the deck?

Filings and press releases describe Nephron’s commitment to purchase a minimum of at least **$400 million** of syringes over ten years, with Sharps becoming Nephron’s exclusive manufacturer of certain prefilled copolymer syringes; the deck uses this to support revenue projections and the business transition to commercial scale.

How is Sharps planning to finance the InjectEZ acquisition described in the deck?

Sharps disclosed that it signed a term sheet for up to **$75 million in debt financing** intended to fund the $50 million InjectEZ acquisition and related growth initiatives, indicating that the capital structure for the transaction would include significant leverage.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

Sharps Technology, Inc. pitch deck slides

Sharps Technology, Inc. pitch deck slide 1 of 23 — Sharps Technology, Inc. pitch deck — slide 1 of 23

Sharps Technology, Inc. pitch deck slide 2 of 23 — Sharps Technology, Inc. pitch deck — slide 2 of 23

Sharps Technology, Inc. pitch deck slide 3 of 23 — Sharps Technology, Inc. pitch deck — slide 3 of 23

Sharps Technology, Inc. pitch deck slide 4 of 23 — Sharps Technology, Inc. pitch deck — slide 4 of 23

Sharps Technology, Inc. pitch deck slide 5 of 23 — Sharps Technology, Inc. pitch deck — slide 5 of 23

Sharps Technology, Inc. pitch deck slide 6 of 23 — Sharps Technology, Inc. pitch deck — slide 6 of 23

What each slide of the Sharps Technology, Inc. pitch deck says

Slide 1

Slide 2

Bl Transformative Deal with Nephron Announced 9/26/23 Pending Acquisition of InjectEZ and $400M 10-Year Supply Agreement Strengthens Path Forward > Signed asset purchase agreement on September 26, 2023 to acquire InjectEZ specialty copolymer syringe manufacturing facility and a 10-Year purchase agreement for over $400 Million from Nephron Pharmaceuticals » Transformative acquisition and purchase agreement enables Sharps to commercialize its innovative copolymer prefillable syringe systems to the healthcare market for the first time > Nephron commits to minimum orders of over $400 Million over 10 years = Product delivery is scheduled for the first quarter of 2024 + Revenue totaling approxima…

Slide 3

Hu Nephron Pharmaceuticals Privately Held World Leader with Over 26 Years of Experience in Contract Manufacturing, 503B Outsourcing, Respiratory Medication Production, and Product Enhancements that Promote Safety Key Highlights: > Recently celebrated a successful $350 million capital raise led by BlackRock Capital Investment Advisors and PNC Bank, National Association (PNC) to support future growth » Significant contract manufacturing business elected as the primary supplier by Abbott Labs for Rapid Covid-19 Test Kits, hiring ~1,500 additional employees through the process » Large privately held conglomerate with clients across leading healthcare/pharmaceutical companies » World's largest b…

Slide 4

Il Significant Developments » Founded in 2017 with a vision to develop innovative drug delivery technology for the healthcare industry + Developed strong product line of patented smart safety syringe systems » Products are FDA, WHO and CE Mark approved and cleared for use by Pfizer and Moderna + Sharps prefillable syringe (PFS) systems will be launched in Q1 of 2024 through the Nephron transaction > September 2021: Sharps names Robert Hayes as CEO «Primary driver for signing recent deal with Nephron * 25years' experience in the healthcare, medical device, and pharmaceutical manufacturing industry + Senior positions at Gerresheimer Pharmaceutical Glass (11 years) and positions at Baxter Heal…

Slide 5

Slide 6

Hl Medical Syringe Market Overview + Syringes are classified into two main groups: + Prefillable syringes: Made of plastic, are filled and stored like vials and disposed of after use + Disposable syringes: Provide an efficient and user-friendly method of single use drug delivery + The market for syringes is currently growing at 4x GDP «Market is increasing due to a steady growth in the number of insured aging people with medical needs + The largest therapeutic areas for prefilled syringes are oncology, followed by diabetes, rheumatoid arthritis, and multiple sclerosis + Innovations in self-administered drug delivery devices such as Sharps’ syringes + Patients’ preference to accept treatment…

Slide text above is read directly from the Sharps Technology, Inc. deck PDF embedded on this page.